Fidelis Animal Health offers exceptional expertise in the acquisition, development, and marketing of unique pharmaceutical formulations that meet specialized veterinary needs. Ethiqa XR is the only pharmaceutical grade extended-release buprenorphine specifically developed for the control of post-procedural pain in mice and rats. Ethiqa XR provides up to 72 hours of pain relief with just one injection. Fidelis Pharmaceuticals is a privately held U.S.-based company serving the world from the Northeast pharmaceutical corridor: Company headquarters is located in New Jersey. Ethiqa XR is manufactured in Pennsylvania. Supply chain sources and manufacturing sites and operations are in full compliance with current Good Manufacturing Practices (cGMPs) regulated by the FDA. Dedicated to providing products that are indexed by the FDA.